ENTA
HEALTHCAREEnanta Pharmaceuticals Inc
$15.24+0.76 (+5.25%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving ENTA Today?
No stock-specific AI insight has been generated for ENTA yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$5.03$17.15
$15.24
Fundamentals
Market Cap$442M
P/E Ratio—
EPS$-3.21
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume345K
Avg Volume (10D)—
Shares Outstanding29.0M
ENTA News
20 articles- Arcturus Therapeutics (ARCT) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Enanta Pharmaceuticals (ENTA) Moves 5.3% Higher: Will This Strength Last?Yahoo Finance·May 7, 2026
- Enanta Pharmaceuticals to Present Data for its Respiratory Syncytial Virus and STAT6 Inhibitor Programs at the American Thoracic Society International Conference 2026Yahoo Finance·May 4, 2026
- Enanta Pharmaceuticals Announces First Participant Dosed in Phase 1 Clinical Trial of EDP-978, an Oral, Once-Daily KIT Inhibitor, in Development for the Treatment of UrticariaYahoo Finance·Apr 13, 2026
- Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at ESCMID Global 2026Yahoo Finance·Apr 7, 2026
- Enanta Pharmaceuticals to Present Data for its STAT6 Inhibitor Program at IMMUNOLOGY2026TM, the Annual Meeting of the American Association of Immunologists (AAI)Yahoo Finance·Mar 30, 2026
- Enanta Pharmaceuticals Pitches RSV Phase 3 Plans, Expands Oral Immunology Pipeline at Citizens ConferenceMarketbeat·Mar 15, 2026
- Enanta Pharmaceuticals to Present at The Citizens Life Sciences ConferenceYahoo Finance·Mar 3, 2026
- What Makes Enanta Pharmaceuticals (ENTA) a New Buy StockYahoo Finance·Feb 12, 2026
- Enanta Pharmaceuticals to Present Preclinical Data for EDP-978, its KIT Inhibitor in Development for the Treatment of Type 2 Immune Diseases, at the 2026 AAAAI Annual MeetingYahoo Finance·Feb 10, 2026
- Enanta Pharmaceuticals (ENTA) Reports Q1 Loss, Tops Revenue EstimatesYahoo Finance·Feb 9, 2026
- Enanta Pharmaceuticals: Fiscal Q1 Earnings SnapshotYahoo Finance·Feb 9, 2026
- Enanta Pharmaceuticals Reports Financial Results for its Fiscal First Quarter Ended December 31, 2025Yahoo Finance·Feb 9, 2026
- JPM26: Enanta outlines strategy to lead in RSV therapeuticsPharmaceutical-technology·Jan 15, 2026
- Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 OutlookYahoo Finance·Jan 8, 2026
- Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare ConferenceYahoo Finance·Jan 5, 2026
- Enanta Pharmaceuticals Insider Ups Holding During YearYahoo Finance·Jan 1, 2026
- Agios Pharmaceuticals (AGIO) Surges 18.6%: Is This an Indication of Further Gains?Yahoo Finance·Dec 26, 2025
- Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains?Yahoo Finance·Dec 22, 2025
- Wall Street Analysts Believe Enanta Pharmaceuticals (ENTA) Could Rally 44.85%: Here's is How to TradeYahoo Finance·Nov 21, 2025
All 20 articles loaded
Price Data
Open$14.67
Previous Close$14.48
Day High$14.94
Day Low$13.81
52 Week High$17.15
52 Week Low$5.03
52-Week Range
$5.03$17.15
$15.24
Fundamentals
Market Cap$442M
P/E Ratio—
EPS$-3.21
Dividend Yield—
Dividend / Share—
ROE-0.6%
Profit Margin-1.1%
Debt / Equity—
Trading
Volume345K
Avg Volume (10D)—
Shares Outstanding29.0M
About Enanta Pharmaceuticals Inc
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. The company is headquartered in Watertown, Massachusetts.
HEALTHCAREBIOTECHNOLOGY
Company Details
Security TypeStock
ExchangeNASDAQ
CurrencyUSD
Round Lot—
SICBIOTECHNOLOGY
CIK—
Composite FIGI—
Share Class FIGI—